Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial

Open access

Abstract

BACKGROUND: Skin barrier dysfunction precedes eczema development. We tested whether daily use of emollient in the first year could prevent eczema in high-risk children. METHODS: We did a multicentre, pragmatic, parallel-group, randomised controlled trial in 12 hospitals and four primary care sites across the UK. Families were approached via antenatal or postnatal services for recruitment of term infants (at least 37 weeks' gestation) at high risk of developing eczema (ie, at least one first-degree relative with parent-reported eczema, allergic rhinitis, or asthma, diagnosed by a doctor). Term newborns with a family history of atopic disease were randomly assigned (1:1) to application of emollient daily (either Diprobase cream or DoubleBase gel) for the first year plus standard skin-care advice (emollient group) or standard skin-care advice only (control group). The randomisation schedule was created using computer-generated code (stratified by recruiting centre and number of first-degree relatives with atopic disease) and participants were assigned to groups using an internet-based randomisation system. The primary outcome was eczema at age 2 years (defined by UK working party criteria) with analysis as randomised regardless of adherence to allocation for participants with outcome data collected, and adjusting for stratification variables. This trial is registered with ISRCTN, ISRCTN21528841. Data collection for long-term follow-up is ongoing, but the trial is closed to recruitment. FINDINGS: 1394 newborns were randomly assigned to study groups between Nov 19, 2014, and Nov 18, 2016; 693 were assigned to the emollient group and 701 to the control group. Adherence in the emollient group was 88% (466 of 532) at 3 months, 82% (427 of 519) at 6 months, and 74% (375 of 506) at 12 months in those with complete questionnaire data. At age 2 years, eczema was present in 139 (23%) of 598 infants with outcome data collected in the emollient group and 150 (25%) of 612 infants in the control group (adjusted relative risk 0·95 [95% CI 0·78 to 1·16], p=0·61; adjusted risk difference -1·2% [-5·9 to 3·6]). Other eczema definitions supported the results of the primary analysis. Mean number of skin infections per child in year 1 was 0·23 (SD 0·68) in the emollient group versus 0·15 (0·46) in the control group; adjusted incidence rate ratio 1·55 (95% CI 1·15 to 2·09). INTERPRETATION: We found no evidence that daily emollient during the first year of life prevents eczema in high-risk children and some evidence to suggest an increased risk of skin infections. Our study shows that families with eczema, asthma, or allergic rhinitis should not use daily emollients to try and prevent eczema in their newborn. FUNDING: National Institute for Health Research Health Technology Assessment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)32984-8

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile *One family was randomly assigned in error at 62 days after birth and so was not included further. The family was not informed of the randomisation, not sent any intervention, and was not contacted for any follow-up. †A sensitivity analysis including all participants was also done using multiple imputation for missing data.
Figure 1 Trial profile *One family was randomly assigned in error at 62 days after birth and so was not included further. The family was not informed of the randomisation, not sent any intervention, and was not contacted for any follow-up. †A sensitivity analysis including all participants was also done using multiple imputation for missing data.CC BY · PubMed Central
Figure 2 Severity of eczema assessed by clinician-reported signs measured by EASI (masked assessment) and parent-reported symptoms measured by POEM (A) Severity at 2 years measured by EASI (masked assessment by research nurse) based on categories in Leshem and colleagues.26 Parent-reported severity at 1 year (B) and 2 years (C) measured by POEM, based on categories in Charman and colleagues.27 These analyses include all infants for whom data were available, regardless of their eczema status. EASI=Eczema Area and Severity Index. POEM=Patient-Oriented Eczema Measure.
Figure 2 Severity of eczema assessed by clinician-reported signs measured by EASI (masked assessment) and parent-reported symptoms measured by POEM (A) Severity at 2 years measured by EASI (masked assessment by research nurse) based on categories in Leshem and colleagues.26 Parent-reported severity at 1 year (B) and 2 years (C) measured by POEM, based on categories in Charman and colleagues.27 These analyses include all infants for whom data were available, regardless of their eczema status. EASI=Eczema Area and Severity Index. POEM=Patient-Oriented Eczema Measure.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 34 references

Cited by

See all 340

Metadata

Authors
Chalmers, J. R., Haines, R. H., Bradshaw, L. E., Montgomery, A. A., Thomas, K. S., Brown, S. J., Ridd, M. J., Lawton, S., Simpson, E. L., Cork, M. J., Sach, T. H., Flohr, C., Mitchell, E. J., Swinden, R., Tarr, S., Davies-Jones, S., Jay, N., Kelleher, M. M., Perkin, M. R., Boyle, R. J., & Williams, H. C.
Affiliations
  • University of Nottingham (GB)
  • University of Dundee (GB)
  • University of Bristol (GB)
  • The Rotherham NHS Foundation Trust (GB)
  • Oregon Health & Science University (US)
  • University of Sheffield (GB)
  • University of East Anglia (GB)
  • King's College London (GB)
  • Sheffield Children's Hospital (GB)
  • Imperial College London (GB)
  • St George's, University of London (GB)
Corresponding author
Williams, Hywel C
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-03
Volume
395
Issue
10228
Pages
962-972
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3009019417
Cited by
317
References
34
Citations by year
2026: 34 · 2025: 37 · 2024: 60 · 2023: 50 · 2022: 61 · 2021: 48 · 2020: 24
FWCI
33.43
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
  • Bristol Research (University of Bristol) (publishedVersion, cc-by)
  • Discovery Research Portal (University of Dundee) (acceptedVersion, cc-by)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • UEA Digital Repository (University of East Anglia) (acceptedVersion)
  • ePrints Soton (University of Southampton) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, other-oa)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Explore Bristol Research (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Celgene
  • University of Dundee
  • Regeneron Pharmaceuticals
  • Wellcome Trust (/Z/15/Z, 106865/Z/15/Z)
  • Dermira
  • National Institute for Health and Care Research (12/67/12, 2014-07-013, PDF-2014-07-013, CDF-2014-07-037, PB-PG-0317-20028, TRF-2017-10-003)
  • Department of Health and Social Care
  • British Association of Dermatologists
  • Imperial College London
  • King's College London
  • Galderma
  • LEO Pharma
  • Genentech
  • Health Technology Assessment Programme (12/67/12)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal skin health care
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
emollients, skin barrier dysfunction, atopic diseases, high-risk infants, allergic rhinitis, asthma, infant skin care
MeSH terms
Dermatitis, Atopic, Dose-Response Relationship, Drug, Drug Administration Schedule, Eczema, Emollients, Female, Follow-Up Studies, United Kingdom, Humans, Infant, Infant, Newborn, Male, Reference Values, Treatment Outcome, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)32984-8
The paper
Chalmers, J. R., Haines, R. H., Bradshaw, L. E., Montgomery, A. A., Thomas, K. S., Brown, S. J., Ridd, M. J., Lawton, S., Simpson, E. L., Cork, M. J., Sach, T. H., Flohr, C., Mitchell, E. J., Swinden, R., Tarr, S., Davies-Jones, S., Jay, N., Kelleher, M. M., Perkin, M. R., . . . Williams, H. C. (2020). Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)32984-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.